Home
|
Inbox
|
Search
|
View Abstract
The Effectiveness, Safety and Tolerability of Pirfenidon Therapy Among Turkish Patients with Idiopathic Pulmonary Fibrosis
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A1653 - The Effectiveness, Safety and Tolerability of Pirfenidon Therapy Among Turkish Patients with Idiopathic Pulmonary Fibrosis
Author Block: I. Hanta1, A. Cilli2, C. Sevinc3, H. Dirol4, S. Kuleci5; 1Chest Diseases, Cukurova University, Adana, Turkey, 2Akdeniz Universitesi Hastanesi, Antalya, Turkey, 3RESPIRATORY MEDICINE DEPT., DOKUZ EYLUL UNIVERSITY SCHOOL OF MEDICINE, IZMIR, Turkey, 4Chest Diseases, Akdeniz University, Antalya, Turkey, 5Cukurova University, Adana, Turkey.
Rationale: Recently, antifibrotic therapy has been approved in idiopathic pulmonary fibrosis (IPF). In this study, we aimed to evaluate effectiveness, safety and tolerability of pirfenidon therapy in Turkish patients with IPF. Methods: In this retrospective study, we were evaluated 60 IPF patients who were taking pirfenidon at least for 6 months. IPF was diagnosed by clinical and radiology and/or histopathology. Patient characteristics, symptoms, pulmonary function tests (FVC, DLCO), 6-minute walk test (6-MWT) and effectiveness of therapy (stability or progression of the disease defined as decline of FVC (≥10%) at baseline and after 6 months of drug therapy), side effects, any hospitalization and mortality were recorded. Results: Of 60 IPF patients, 44 (73.4%) were male. While 46 (76.7%) IPF patients were stable during therapy course, 14 (23.3%) IPF patients had progressed according to decline in FVC ≥ 10%. During 6 months of antifibrotic therapy, in 9 (15.0%) IPF patients had exacerbation, and in 10 (16.7%) patients had all-cause hospitalization and one (1.7%) patient died. At least one side effect due to therapy were encountered in 33 (55.0%) IPF patients. Leading side effects were gastrointestinal symptoms (n=21, 35.0%) and photosensitivity (n=8, 13.3%). While in 16 (26.7%) patients, therapy dose was decreased, in only one (1.7%) patients therapy was discontinued due to intolerability. Conclusions: We concluded that pirfenidone therapy for IPF was effective and tolerable, and also had relatively acceptable side effects in our Turkish patients with IPF.
Author Block: I. Hanta1, A. Cilli2, C. Sevinc3, H. Dirol4, S. Kuleci5; 1Chest Diseases, Cukurova University, Adana, Turkey, 2Akdeniz Universitesi Hastanesi, Antalya, Turkey, 3RESPIRATORY MEDICINE DEPT., DOKUZ EYLUL UNIVERSITY SCHOOL OF MEDICINE, IZMIR, Turkey, 4Chest Diseases, Akdeniz University, Antalya, Turkey, 5Cukurova University, Adana, Turkey.
Rationale: Recently, antifibrotic therapy has been approved in idiopathic pulmonary fibrosis (IPF). In this study, we aimed to evaluate effectiveness, safety and tolerability of pirfenidon therapy in Turkish patients with IPF. Methods: In this retrospective study, we were evaluated 60 IPF patients who were taking pirfenidon at least for 6 months. IPF was diagnosed by clinical and radiology and/or histopathology. Patient characteristics, symptoms, pulmonary function tests (FVC, DLCO), 6-minute walk test (6-MWT) and effectiveness of therapy (stability or progression of the disease defined as decline of FVC (≥10%) at baseline and after 6 months of drug therapy), side effects, any hospitalization and mortality were recorded. Results: Of 60 IPF patients, 44 (73.4%) were male. While 46 (76.7%) IPF patients were stable during therapy course, 14 (23.3%) IPF patients had progressed according to decline in FVC ≥ 10%. During 6 months of antifibrotic therapy, in 9 (15.0%) IPF patients had exacerbation, and in 10 (16.7%) patients had all-cause hospitalization and one (1.7%) patient died. At least one side effect due to therapy were encountered in 33 (55.0%) IPF patients. Leading side effects were gastrointestinal symptoms (n=21, 35.0%) and photosensitivity (n=8, 13.3%). While in 16 (26.7%) patients, therapy dose was decreased, in only one (1.7%) patients therapy was discontinued due to intolerability. Conclusions: We concluded that pirfenidone therapy for IPF was effective and tolerable, and also had relatively acceptable side effects in our Turkish patients with IPF.
|
Home
|
Inbox
|
Search
|